 Connection
Myron Levin to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Myron Levin has written about Dose-Response Relationship, Drug.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.096 |
|
|
|
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
Score: 0.044
-
Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Mol Cancer Ther. 2015 Nov; 14(11):2569-75.
Score: 0.021
-
Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
Score: 0.020
-
Berkowitz FE, Levin MJ. Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus. Antimicrob Agents Chemother. 1985 Aug; 28(2):207-10.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|